Point prevalence of drug prescriptions for elderly and non-elderly inpatients in a teaching hospital
Keywords:
Elderly, Cross-sectional study, Prescription, Inpatients, Pharmacoepidemiology, General hospital, AgingAbstract
CONTEXT: Age-related pharmacokinetic and pharmacodynamic changes have been extensively documented, and several concurrent diseases may underlie multiple drug therapy in the elderly. As a result, the risk of adverse drug reactions and drug interactions increases among aged patients. How ever, only a few studies have compared the prescribing patterns for different age groups of hospitalized patients or have evaluated the effect of age on drug prescription. OBJECTIVE: To compare the prevalence of drug prescriptions for elderly inpatients, with those for non elderly inpatients, in order to assess age-related differences in the number of prescribed drugs, drug choices and prescribed doses, and to evaluate the prescription appropriateness for the elderly patients. TYPE OF STUDY: Cross-sectional survey. SETTING: 400-bed tertiary care general teaching hospital. PARTICIPANTS: All inpatients on one day of June 1995, except for the Intensive Care Unit and for the Departments of Psychiatry, Pediatrics and Obstetrics and Gynecology. PROCEDURES: All medicines prescribed to the eligible patients on the study day were recorded from the prescription sheets provided by the hospital pharmacy. MAIN MEASUREMENTS: Name, therapeutic class, and mean daily dose of the prescribed drugs. RESULTS: Of the 273 eligible inpatients, 46.5% were 14-44 years old, 33% were 45-64 years old and 20.5% were > 64 years old. Cancer was significantly more frequent among the elderly. The mean number of prescribed drugs was five for all age groups. The five most prescribed drugs for all patients were dipyrone, ranitidine, dipyrone in a fixeddose combination, metoclopramide and cefazolin. The elderly had significantly more prescriptions for insulin, furosemide and enoxaparin. For most drugs, the mean prescribed dose showed that there was no dose adjustment for elderly patients, and drug choices for this age group were sometimes questionable. CONCLUSIONS: There was little variation in the prescribing patterns for the elderly when compared with the other age strata.
Downloads
References
Ministério da Saúde. Informações de Saúde. DATASUS. Avail- able from URL: http://tabnet.datasus.gov.br/tabnet/tabnet.htm. Accessed in 2003 (Oct 21).
Kalache A, Veras RP, Ramos LR. O envelhecimento da população mundial: um desafio novo. [The ageing of the world’s popula- tion: a new challenge]. Rev Saúde Pública. 1987;21(3):200-10.
Montamat SC, Cusack BJ, Vestal RE. Management of drug therapy in the elderly. N Engl J Med. 1989;321(5):303-9.
Greenblatt DJ, Sellers EM, Shader RI. Drug therapy: drug dis- position in old age. N Engl J Med. 1982;306(18):1081-8.
Nolan L, O’Malley K. Prescribing for the elderly: Part II. Pre- scribing patterns: differences due to age. J Am Geriatr Soc. 1988;36(3):245-54.
Sotaniemi E, Palva IP. The use of polypharmaceutical drug therapy in a medical ward. Ann Clin Res. 1972;4(3):158-64.
Nielsen IK, Osterlind AW, Christiansen LV, et al. Drug con- sumption and age in a department of internal medicine. Dan Med Bull. 1981;28(2):71-3.
Organizacao Mundial da Saude. Manual da classificação estatística internacional de doenças lesões e causas de óbito. São Paulo: Centro da OMS Classif Doencas em Port, 1978.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
World Health Organization. Guidelines for ATC classification and DDD assignment. Oslo: WHO Collaborating Center for Drug Statistics Methodology; 1996.
Christopher LJ, Ballinger BR, Shepherd AM, Ramsay, A, Crooks G. Drug prescribing patterns in the elderly: a cross-sectional study of inpatients. Age Ageing. 1978;7(2):74-82.
Rowe JW. Health care of the elderly. N Engl J Med. 1985;312(13):827-35.
Miller RR. Drug surveillance utilizing epidemiologic methods. A report from the Boston Collaborative Drug Surveillance Pro- gram. Am J Hosp Pharm. 1973;30(7):584-92.
Reynolds JEF, editor. Martindale The Extra Pharmacopoeia. 30th ed. London: Pharmaceutical Press; 1993.
Remillard AJ. A pharmacoepidemiological evaluation of anti- cholinergic prescribing patterns in the elderly. Pharma- coepidemiol Drug Saf. 1996;5:155-64.
Cusack BJ, Nielson CP, Vestal RE. Geriatric clinical pharma- cology and therapeutics. In: Speight TM, Holford NHG, edi- tors. Avery’s Drug Treatment. 4th ed. Auckland: Adis Press; 1997.p.173-223.
Lisi DM. Drug-induced constipation. Arch Intern Med. 1994;154(4):461, 465, 468.
Shorr RI, Griffin MR, Daugherty JR, Ray WA. Opioid analge- sics and the risk of hip fracture in the elderly: codeine and propoxyphene. J Gerontol. 1992;47(4):M111-5.
World Health Organization. Drugs for the elderly. Copenha- gen: WHO; 1989.
Porter J, Jick H. Drug-induced anaphylaxis, convulsions, deaf- ness, and extrapyramidal symptoms. Lancet. 1977; 1(8011):587-8.
Crooks J. Rational therapeutics in the elderly. J Chron Dis. 1983;36(1):59-65
Scharf S, Christophidis N. Relevance of pharmacokinetics and pharmacodynamics. Med J Aust. 1993;158(6):395-402.
Bennet WM. Guide to drug dosage in renal failure. In: Speight TM, Holford NHG, editors. Avery’s Drug Treatment. 4th ed. Auckland: Adis Press; 1997.p.1725-56.
Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P. Age and severe adverse drug reactions caused by nifedipine and verapamil. Gruppo Italiano di Farmacovigilanza nell’ Anziano (GIFA). J Clin Epidemiol. 1996;49(8):921-8.
Hebert MF. Guide to drug dosage in hepatic disease. In: Speight TM, Holford NHG, editors. Avery’s Drug Treatment. 4th ed. Auckland: Adis Press; 1997.p.1761-92.
Yusuf S. Calcium antagonists in coronary artery disease and hypertension. Time for reevaluation? Circulation. 1995; 92(5):1079-82.
Pahor M, Guralnik JM, Corti MC, Foley DJ, Carbonin P, Havlik RJ. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc. 1995;43(11):1191-7.
Ebly EM. Nifedipine and mortality risk in the elderly: relevance of drug formulation, dose and duration. Pharmacoepidemiol Drug Saf. 2000;9:11-23.
Ray WA, Griffin MR, Schaffner W, Baugh DK, Melton LJ. Psychotropic drug use and the risk of hip fracture. N Engl J Med. 1987;316(7):363-9.
Tapson VF, Hull RD. Management of venous thromboembolic disease. The impact of low-molecular-weight heparin. Clin Chest Med. 1995;16(2):281-94.
Owings JT, Blaisdell FW. Low-dose heparin thromboembolism prophylaxis. Arch Surg. 1996;131(10):1069-73.
